Robert C. Ferris

AlphaMed is a small business headquartered in Massachusetts. An exclusive patent license from MIT enables AlphaMed to develop and market isotopes using photonuclear technology. Agreements are in place with Rensselaer Polytechnic Institute for irradiation services and with the Pacific Northwest National Lab to process AlphaMed's isotopes and prepare them for shipment. The company has relationships with Argonne National Laboratory and is developing relationships with selected Russian laboratories under the Initiatives for Proliferation Prevention program. AlphaMed is a member of the United States Industry Coalition, Inc., a non-profit association of U.S. companies and universities dedicated to the nonproliferation of weapons of mass destruction through commercialization of technologies for peaceful purposes. AlphaMed's primary focus is to produce radioisotopes that have shown promise in cancer therapies and treatment of other diseases. It has received competitive contracts from the Department of Energy that support the development and delivery of alpha-emitting radionuclides. The company has been awarded a grant from the Department of Energy to privatize the production of radioisotope generators critical to research being conducted by the National Cancer Institute, the University of Chicago, and private radiopharmaceutical companies. AlphaMed and Pacific Northwest National Laboratory have agreed to collaborate to design, test and evaluate new and existing technologies for processing uranium-232 and producing radium-224/lead-212/bismuth-212 radionuclide generators. Lead-212 and bismuth-212 are alpha emitting radioisotopes that are used for research in radioimmunotherapy with important applications that include treating leukemia and metastatic cancers.